Detect the impact of different adjuvants

The Epibase® Dendritic Cell Activation Assay uses human dendritic cells (DC) to assess the impact of  your vaccine on the innate immune response. Cytokine/chemokine profiles are assessed after incubation of the DC with the vaccine leads. The assay has been designed to detect the impact of different adjuvants included in the vaccine which may impact the quality of the immune response.  

Dendritic Cell Activation Assay

  • Resting DC are generated from healthy donors and loaded with test protein ± adjuvant
  • DC phenotype is assessed before and after treatment by flow cytometry (DC viability and key DC activation markers)
  • Supernatant samples are analyzed for the secretion of key DC cytokines/chemokines by Luminex®
  • Standard cytokine/chemokine panel includes: FGF basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12(p70), IL-13, IL-15, IL-17, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNFα, VEGF
  • Customized cytokine/chemokine panels may also be created upon request
  • LPS (lipopolysaccharide) is included as a typical control and potent activator of DC cytokine expression